Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Lauren Burke
Based on 1 article published since 2009
(Why 1 article?)
||||

Between 2009 and 2019, Lauren Burke wrote the following article about Melanoma.
 
+ Citations + Abstracts
1 Article Implementing a Program of Talimogene laherparepvec. 2018

Collichio, Frances / Burke, Lauren / Proctor, Amber / Wallack, Diana / Collichio, Anthony / Long, Patricia K / Ollila, David W. ·Division of Hematology-Oncology, Department of Medicine, The University of North Carolina, Chapel Hill, NC, USA. fcollich@med.unc.edu. · Department of Radiology, The University of North Carolina, Chapel Hill, NC, USA. · Department of Pharmacy, The University of North Carolina, Chapel Hill, NC, USA. · The Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA. · Boston University, Boston, MA, USA. · Division of Surgical Oncology, The University of North Carolina, Chapel Hill, NC, USA. ·Ann Surg Oncol · Pubmed #29417403.

ABSTRACT: BACKGROUND: Oncolytic viruses are genetically engineered or naturally occurring viruses that selectively replicate in cancer cells without harming normal cells. Talimogene laherparepvec (Imlygic PURPOSE: As a biologic product, use of T. laherparepvec in the clinical setting requires pretreatment planning and a unique systematic approach to deliver the therapy. The processes we describe herein could be adopted by other centers that choose to prescribe T. laherparepvec. METHODS: We studied our clinical trial experience with T. laherparepvec before we embarked on using commercially available T. laherparepvec. We created a standard operating procedure (SOP) with multidisciplinary buy-in and oversight from leadership in Infection Control at our institution. We reflected on clinical cases and the actual procedures of administering T. laherparepvec to create the SOP. RESULTS: The preimplementation planning, patient selection, identification of lesions to treat, the actual procedure, and ongoing assessment of patients are described. Tumoral-related factors that lead to unique challenges are described. CONCLUSIONS: A process to ensure safe and responsible implementation of a program to administer T. laherparepvec for treatment of melanoma may improve the quality of treatment for patients who suffer from advanced melanoma.